JP2023535790A5 - - Google Patents

Info

Publication number
JP2023535790A5
JP2023535790A5 JP2023505743A JP2023505743A JP2023535790A5 JP 2023535790 A5 JP2023535790 A5 JP 2023535790A5 JP 2023505743 A JP2023505743 A JP 2023505743A JP 2023505743 A JP2023505743 A JP 2023505743A JP 2023535790 A5 JP2023535790 A5 JP 2023535790A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
unsubstituted
compound according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535790A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/071212 external-priority patent/WO2022023447A2/en
Publication of JP2023535790A publication Critical patent/JP2023535790A/ja
Publication of JP2023535790A5 publication Critical patent/JP2023535790A5/ja
Pending legal-status Critical Current

Links

JP2023505743A 2020-07-28 2021-07-28 縮合二環式raf阻害薬及びその使用方法 Pending JP2023535790A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057536P 2020-07-28 2020-07-28
US63/057,536 2020-07-28
PCT/EP2021/071212 WO2022023447A2 (en) 2020-07-28 2021-07-28 Fused bicyclic raf inhibitors and methods for use thereof

Publications (2)

Publication Number Publication Date
JP2023535790A JP2023535790A (ja) 2023-08-21
JP2023535790A5 true JP2023535790A5 (enExample) 2024-08-06

Family

ID=77499800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505743A Pending JP2023535790A (ja) 2020-07-28 2021-07-28 縮合二環式raf阻害薬及びその使用方法

Country Status (11)

Country Link
US (3) US11858930B2 (enExample)
EP (1) EP4188552A2 (enExample)
JP (1) JP2023535790A (enExample)
KR (1) KR20230058399A (enExample)
CN (1) CN116601150A (enExample)
AU (1) AU2021314955A1 (enExample)
BR (1) BR112023001557A2 (enExample)
CA (1) CA3187514A1 (enExample)
IL (1) IL300113A (enExample)
MX (1) MX2023001275A (enExample)
WO (1) WO2022023447A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188552A2 (en) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
CN116143633A (zh) * 2022-12-30 2023-05-23 浙江巍华新材料股份有限公司 一种制备2,5-二氯-4-三氟甲基苯胺的方法
AU2024223957A1 (en) * 2023-02-17 2025-09-04 Jazz Pharmaceuticals Ireland Limited Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
JPS6058915A (ja) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPH0617309B2 (ja) 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
DE3611229A1 (de) 1986-04-04 1987-10-08 Basf Ag Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5698550A (en) 1993-06-14 1997-12-16 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
WO1995022963A1 (en) 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Drug targeting system, method for preparing same and its use
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
WO1996032930A1 (en) 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
FI20011507A0 (fi) 2001-07-10 2001-07-10 Orion Corp Uusia yhdisteitä
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
CN1690056A (zh) 2004-04-30 2005-11-02 北京大学 三个化合物及其制备方法和用途
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
PL2797888T3 (pl) 2011-12-31 2016-12-30 Połączone związki tricykliczne jako inhibitory kinazy raf
GB201416186D0 (en) * 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
CN109503659B (zh) 2019-01-03 2021-06-18 凯特立斯(深圳)科技有限公司 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用
EP4188552A2 (en) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
IL300110A (en) 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Chiral synthesis of fused bicyclic raf inhibitors

Similar Documents

Publication Publication Date Title
JP2023535790A5 (enExample)
ES2985987T3 (es) Derivado de N-(aza-aril)ciclolactam-1-carboxamida, método de preparación correspondiente y uso del mismo
AU2019378184B2 (en) 2,3-dihydro-1H-pyrrolo(3,4-c)pyridin-1-one derivatives as HPK1 inhibitors for the treatment of cancer
RU2606497C2 (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP2018532737A5 (enExample)
CN107108588B (zh) 可用于治疗癌症的稠合双环(杂)芳香族化合物
DK2197878T3 (en) FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases
JP2016513660A5 (enExample)
CN112334451A (zh) 作为激酶抑制剂的杂环化合物
JP2008528467A5 (enExample)
JP2009543771A5 (enExample)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP2020503299A5 (enExample)
RU2014153627A (ru) Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ
WO2019018584A1 (en) HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
JP2012511564A5 (enExample)
WO2021030623A1 (en) Heterocyclic compounds as kinase inhibitors
JP2016537358A (ja) ジヒドロピリミジン化合物及び医薬におけるその適用
JP2010540458A5 (enExample)
AU2019316858B2 (en) Smad3 inhibitors
CA2974788A1 (en) A 2-pyrimidinyl substituted pyridinyl heterocyclic compound and a pharmaceutical composition comprising the same
TW202313048A (zh) 組合療法
JP2021523168A5 (enExample)
AU2019372121A1 (en) Heterocyclic compounds as BET inhibitors
CA3136492A1 (en) Heterocyclic compounds and uses thereof